BOSENTAN - endothelin receptor antagonist

BOSENTAN - endothelin receptor antagonist

Activation of the endothelin system has been demonstrated in the plasma and lung tissue of PAH (Pulmonary Artery Hypertension) patients. Although it is not clear if the increases in endothelin plasma levels are a cause or a consequence of PH (Pulmonary Hypertension), the data supports a prominent ro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of human and health sciences 2018-11, Vol.3 (1), p.10
Hauptverfasser: Singal, Kiran Kumar, Singal, Neerja, Passi, Paras, Singla, Mohit, Gupta, Nitin, Sumit, Gautam
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 10
container_title International journal of human and health sciences
container_volume 3
creator Singal, Kiran Kumar
Singal, Neerja
Passi, Paras
Singla, Mohit
Gupta, Nitin
Sumit, Gautam
description Activation of the endothelin system has been demonstrated in the plasma and lung tissue of PAH (Pulmonary Artery Hypertension) patients. Although it is not clear if the increases in endothelin plasma levels are a cause or a consequence of PH (Pulmonary Hypertension), the data supports a prominent role for the endothelin system in the pathogenesis of PAH. Bosentan is an endothelin receptor antagonist used in the treatment of Primary pulmonary hypertension (PPH) which is a progressive disease with high mortality and administration of the orally active, dual endothelin receptor antagonist bosentan improves exercise endurance, haemodynamics, and functional class over the short term. First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension.International Journal of Human and Health Sciences Vol. 03 No. 01 January’19. Page : 10-13
doi_str_mv 10.31344/ijhhs.v3i1.66
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_31344_ijhhs_v3i1_66</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_31344_ijhhs_v3i1_66</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_31344_ijhhs_v3i1_663</originalsourceid><addsrcrecordid>eNpjYBAzNNAzNjQ2MdHPzMrIKNYrM8401DMzY2LgNDI1MtY1szSKYEFiczDwFhdnGRgYGBmaG1iamXEyaDr5B7v6hTj6KegqpOal5JdkpOZk5ikUpSanFpTkFykk5pUkpufnZRaX8DCwpiXmFKfyQmluBj031xBnD93kovzi4qLUtPiCoszcxKLKeEODeLCb4sFuige5Kd7MzJhkDQCS7UAn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>BOSENTAN - endothelin receptor antagonist</title><source>DOAJ Directory of Open Access Journals</source><creator>Singal, Kiran Kumar ; Singal, Neerja ; Passi, Paras ; Singla, Mohit ; Gupta, Nitin ; Sumit, Gautam</creator><creatorcontrib>Singal, Kiran Kumar ; Singal, Neerja ; Passi, Paras ; Singla, Mohit ; Gupta, Nitin ; Sumit, Gautam</creatorcontrib><description>Activation of the endothelin system has been demonstrated in the plasma and lung tissue of PAH (Pulmonary Artery Hypertension) patients. Although it is not clear if the increases in endothelin plasma levels are a cause or a consequence of PH (Pulmonary Hypertension), the data supports a prominent role for the endothelin system in the pathogenesis of PAH. Bosentan is an endothelin receptor antagonist used in the treatment of Primary pulmonary hypertension (PPH) which is a progressive disease with high mortality and administration of the orally active, dual endothelin receptor antagonist bosentan improves exercise endurance, haemodynamics, and functional class over the short term. First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension.International Journal of Human and Health Sciences Vol. 03 No. 01 January’19. Page : 10-13</description><identifier>ISSN: 2523-692X</identifier><identifier>EISSN: 2523-692X</identifier><identifier>DOI: 10.31344/ijhhs.v3i1.66</identifier><language>eng</language><ispartof>International journal of human and health sciences, 2018-11, Vol.3 (1), p.10</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Singal, Kiran Kumar</creatorcontrib><creatorcontrib>Singal, Neerja</creatorcontrib><creatorcontrib>Passi, Paras</creatorcontrib><creatorcontrib>Singla, Mohit</creatorcontrib><creatorcontrib>Gupta, Nitin</creatorcontrib><creatorcontrib>Sumit, Gautam</creatorcontrib><title>BOSENTAN - endothelin receptor antagonist</title><title>International journal of human and health sciences</title><description>Activation of the endothelin system has been demonstrated in the plasma and lung tissue of PAH (Pulmonary Artery Hypertension) patients. Although it is not clear if the increases in endothelin plasma levels are a cause or a consequence of PH (Pulmonary Hypertension), the data supports a prominent role for the endothelin system in the pathogenesis of PAH. Bosentan is an endothelin receptor antagonist used in the treatment of Primary pulmonary hypertension (PPH) which is a progressive disease with high mortality and administration of the orally active, dual endothelin receptor antagonist bosentan improves exercise endurance, haemodynamics, and functional class over the short term. First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension.International Journal of Human and Health Sciences Vol. 03 No. 01 January’19. Page : 10-13</description><issn>2523-692X</issn><issn>2523-692X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpjYBAzNNAzNjQ2MdHPzMrIKNYrM8401DMzY2LgNDI1MtY1szSKYEFiczDwFhdnGRgYGBmaG1iamXEyaDr5B7v6hTj6KegqpOal5JdkpOZk5ikUpSanFpTkFykk5pUkpufnZRaX8DCwpiXmFKfyQmluBj031xBnD93kovzi4qLUtPiCoszcxKLKeEODeLCb4sFuige5Kd7MzJhkDQCS7UAn</recordid><startdate>20181102</startdate><enddate>20181102</enddate><creator>Singal, Kiran Kumar</creator><creator>Singal, Neerja</creator><creator>Passi, Paras</creator><creator>Singla, Mohit</creator><creator>Gupta, Nitin</creator><creator>Sumit, Gautam</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20181102</creationdate><title>BOSENTAN - endothelin receptor antagonist</title><author>Singal, Kiran Kumar ; Singal, Neerja ; Passi, Paras ; Singla, Mohit ; Gupta, Nitin ; Sumit, Gautam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_31344_ijhhs_v3i1_663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singal, Kiran Kumar</creatorcontrib><creatorcontrib>Singal, Neerja</creatorcontrib><creatorcontrib>Passi, Paras</creatorcontrib><creatorcontrib>Singla, Mohit</creatorcontrib><creatorcontrib>Gupta, Nitin</creatorcontrib><creatorcontrib>Sumit, Gautam</creatorcontrib><collection>CrossRef</collection><jtitle>International journal of human and health sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singal, Kiran Kumar</au><au>Singal, Neerja</au><au>Passi, Paras</au><au>Singla, Mohit</au><au>Gupta, Nitin</au><au>Sumit, Gautam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BOSENTAN - endothelin receptor antagonist</atitle><jtitle>International journal of human and health sciences</jtitle><date>2018-11-02</date><risdate>2018</risdate><volume>3</volume><issue>1</issue><spage>10</spage><pages>10-</pages><issn>2523-692X</issn><eissn>2523-692X</eissn><abstract>Activation of the endothelin system has been demonstrated in the plasma and lung tissue of PAH (Pulmonary Artery Hypertension) patients. Although it is not clear if the increases in endothelin plasma levels are a cause or a consequence of PH (Pulmonary Hypertension), the data supports a prominent role for the endothelin system in the pathogenesis of PAH. Bosentan is an endothelin receptor antagonist used in the treatment of Primary pulmonary hypertension (PPH) which is a progressive disease with high mortality and administration of the orally active, dual endothelin receptor antagonist bosentan improves exercise endurance, haemodynamics, and functional class over the short term. First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension.International Journal of Human and Health Sciences Vol. 03 No. 01 January’19. Page : 10-13</abstract><doi>10.31344/ijhhs.v3i1.66</doi></addata></record>
fulltext fulltext
identifier ISSN: 2523-692X
ispartof International journal of human and health sciences, 2018-11, Vol.3 (1), p.10
issn 2523-692X
2523-692X
language eng
recordid cdi_crossref_primary_10_31344_ijhhs_v3i1_66
source DOAJ Directory of Open Access Journals
title BOSENTAN - endothelin receptor antagonist
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T22%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BOSENTAN%20-%20endothelin%20receptor%20antagonist&rft.jtitle=International%20journal%20of%20human%20and%20health%20sciences&rft.au=Singal,%20Kiran%20Kumar&rft.date=2018-11-02&rft.volume=3&rft.issue=1&rft.spage=10&rft.pages=10-&rft.issn=2523-692X&rft.eissn=2523-692X&rft_id=info:doi/10.31344/ijhhs.v3i1.66&rft_dat=%3Ccrossref%3E10_31344_ijhhs_v3i1_66%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true